Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971215 | 0.87 | GNAO1 (0.50) | EPHX1EPHX2GNAI3GNAO1GNAI1 | |
| SCHEMBL13934478 | 0.85 | SMN1; SMN2 (0.46) | EPHX1EPHX2SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL13617466 | 0.84 | SMN1; SMN2 (0.52) | EPHX1EPHX2SMN1; SMN2 | |
| Acetic Acid SCHEMBL30331117 | 0.81 | SMN1; SMN2 (0.46) | EPHX1EPHX2SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL12156863 | 0.80 | CACNA1I (0.48) | EPHX1HTR4 | |
| SCHEMBL23841920 | 0.80 | EPHX1 (0.42) | EPHX1EPHX2SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL12156725 | 0.80 | SMN1; SMN2 (0.47) | EPHX1EPHX2SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL10268818 | 0.79 | NCF1 (0.48) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12442952 | 0.79 | EPHX1 (0.41) | EPHX1EPHX2SMN1; SMN2L3MBTL1HTR4 | |
| SCHEMBL22703731 | 0.78 | HTR4 (0.43) | EPHX1EPHX2SMN1; SMN2L3MBTL1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-0700383-A1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | EPHX1 251/4885EPHX2 405/4885SMN1; SMN2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.